NeuBase Therapeutics (NeuBase Therapeutics) Debt-to-Equity : 0.58 (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Debt-to-Equity?

NeuBase Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.50 Mil. NeuBase Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.83 Mil. NeuBase Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $9.14 Mil. NeuBase Therapeutics's debt to equity for the quarter that ended in Sep. 2023 was 0.58.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NeuBase Therapeutics's Debt-to-Equity or its related term are showing as below:

NBSE' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.95 Med: 0.01 Max: 0.58
Current: 0.58

During the past 13 years, the highest Debt-to-Equity Ratio of NeuBase Therapeutics was 0.58. The lowest was -5.95. And the median was 0.01.

NBSE's Debt-to-Equity is ranked worse than
78% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs NBSE: 0.58

NeuBase Therapeutics Debt-to-Equity Historical Data

The historical data trend for NeuBase Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Debt-to-Equity Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Debt-to-Equity

Get a 7-Day Free Trial

0.01

-5.95

0.01

0.12

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.26	0.32	0.39	0.49	0.58

Competitive Comparison of NeuBase Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, NeuBase Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuBase Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Debt-to-Equity falls into.

NeuBase Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NeuBase Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Sep. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.639	+	5.904)	/	54.07
	=	0.12

NeuBase Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.501	+	4.834)	/	9.137
	=	0.58

NeuBase Therapeutics (NAS:NBSE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NeuBase Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

O7P:Germany O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Executives

Symetryx Corp	10 percent owner	2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann	officer: COO	700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei	officer: See Remarks	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall	director	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles	director	2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast	director
Dietrich A Stephan	director, 10 percent owner, officer: President and CEO	213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc	10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801